Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region

Abstract

Background: Clinical remission is an attainable goal for Rheumatoid Arthritis (RA). However, data on RA remission rates from multinational studies in the Asia-Pacific region are limited. We conducted a crosssectional multicentric study to evaluate the clinical remission status and the related factors in RA patients in the Asia-Pacific region. Methods: RA patients receiving standard care were enrolled consecutively from 17 sites in 11 countries from APLAR RA SIG group. Data were collected on-site by rheumatologists with a standardized casereport form. Remission was analyzed by different definitions including disease activity score using 28 joints (DAS28) based on ESR and CRP, clinical disease activity index (CDAI), simplified disease activity index (SDAI), Boolean remission definition, and clinical deep remission (CliDR). Logistic regression was used to determine related factors of remission. Findings: A total of 2010 RA patients was included in the study, the overall remission rates were 62 • 3% (DAS28-CRP), 35 • 5% (DAS28-ESR), 30 • 8% (CDAI), 26 • 5% (SDAI), 24 • 7% (Boolean), and 17 • 1% (CliDR), respectively, and varied from countries to countries in the Asia-Pacific region. Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) prescription rate was low (17 • 9%). Compared to patients in non-remission, patients in remission had higher rates of b/tsDMARDs usage and lower rates of

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

“…13 In another study of patients between 2017 and 2019, the remission rate was calculated by the DAS28-CRP and Boolean criteria, and was found to increase to 62% and 24.7%, respectively. 14 Those studies included 30% and 18% of patients who were treated with biologic or targeted synthetic DMARDs (b/tsDMARDs), respectively. 13 , 14 The remission rate is lower when it is defined by more stringent criteria.…”

“… 14 Those studies included 30% and 18% of patients who were treated with biologic or targeted synthetic DMARDs (b/tsDMARDs), respectively. 13 , 14 The remission rate is lower when it is defined by more stringent criteria. 14 , 15 To date, different definitions of remission have been used and different proportions of patients treated with b/tsDMARDs have been included.…”

“…13 , 14 The remission rate is lower when it is defined by more stringent criteria. 14 , 15 To date, different definitions of remission have been used and different proportions of patients treated with b/tsDMARDs have been included.…”

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

“…Despite the widespread availability of disease-modifying antirheumatic drugs (DMARDs), many patients are not able to achieve and sustain remission of rheumatoid arthritis (RA) [ 1 , 2 ]. Failed or inadequate response (IR) to DMARDs is associated with poor prognosis; additionally, several disease characteristics have been identified as poor prognostic factors (PPFs) in early RA, including seropositivity defined by rheumatoid factor (RF) or cyclic citrullinated peptide (CCP) positive, high baseline high-sensitivity C-reactive protein (hsCRP), high baseline disease activity, and extant bone erosion at disease onset [ 3 – 5 ].…”

Orthorexia Nervosa Practices in Rheumatoid Arthritis: The DORA Study

“…Due to the heterogenous manifestations of the disease, remission and prognosis are difficult to predict [ 70 ]. Subsequently, contradictory factors have been associated with remission in the literature among patients with RA, including older age, female gender, obesity status, history of smoking, comorbidities, fewer EAMs, use of DMARDs, treatment with GC, poor functional status, increased disease activity and erythrocyte sedimentation rate (ESR) at the time of diagnosis [ 41 , 71 , 72 , 73 ]. All of the evidence points to the fact that relapse in RA is difficult to predict.…”